gadoterate; gadoterate meglumine (Doterem)
Jump to navigation
Jump to search
Indications
Adverse effects
- low risk for nephrogenic Systemic Fibrosis[2]
More general terms
References
- ↑ PubChem: 71300410
- ↑ 2.0 2.1 2.2 Brett AS Is Nephrogenic Systemic Fibrosis Following Gadolinium-Enhanced Imaging Still a Problem? NEJM Journal Watch. Jan 25, 2018 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71300410
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=158536
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71300448
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71300392
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71464587